PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)

NCT05983588 | Active Not Recruiting Phase 2

• 1 other identifier: PROFIL-2088-SIM-0032-I
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 2

Brief Summary

Corticobasal syndrome (CBS) is a rapidly progressive neurodegenerative disorder with an average survival time of about 6-8 years after the first clinical manifestation. No potent symptomatic treatment is currently available. A disease-modifying therapy does not exist either. Neuroinflammation is key to the pathogenesis in neurodegenerative diseases with Tau- and/or AD-pathology. There is strong evidence that phenylbutyrate can modulate microglial function by enhancing their phagocytic activity, most likely by epigenetic mechanisms. So the main goal of this clinical trial is to study a potential disease-modifying effect of treatment with glycerol phenylbutyrate (GPB), which is a prodrug of phenylbutyric acid, for 26 weeks assessed by the levels of the biomarker neurofilament light chain (NfL) indicating disease progression in CBS. Given the aggressive nature of CBS, it is feasible to study effects of GPB on plasma NfL levels.

Conditions

Corticobasal Syndrome (CBS)

Outcome Measures

Primary Outcomes (1)

• To assess the efficacy of glycerol phenylbutyrate vs. placebo in reducing the levels of neurofilament light chain (NfL) during 26 weeks of exposure to glycerol phenylbutyrate as well as safety and tolerability of glycerol phenylbutyrate in patients with

  To assess the efficacy of glycerol phenylbutyrate vs. placebo in reducing the levels of neurofilament light chain (NfL) during 26 weeks of exposure to glyc-erol phenylbutyrate as well as safety and tolerability of glycerol phenylbutyrate in patients with CBS.

  26 weeks (between V1 and V3)

Secondary Outcomes (9)

• To assess longitudinal changes in clinical scales

  26 weeks (between V1 and V3)

• To assess longitudinal changes in clinical scales

  26 weeks (between V1 and V3)

• To assess longitudinal changes in clinical scales

  26 weeks (between V1 and V3)

• To assess longitudinal changes in clinical scales

  26 weeks (between V1 and V3)

• To assess longitudinal changes in clinical scales

  26 weeks (between V1 and V3)

Study Arms (2)

Verum

EXPERIMENTAL

RAVICTI 1.1 g/ml oral liquid (glycerol phenylbutyrate (GPB)) Duration of Treatment: 26 weeks, twice daily

Drug: RAVICTI 1.1 g/ml

Placebo

PLACEBO COMPARATOR

Matching Placebo, oral liquid Duration of Treatment: 26 weeks, twice daily

Drug: Placebo

Interventions

RAVICTI 1.1 g/ml DRUG

Duration of Treatment: 26 weeks, twice daily Dosage: * weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo) * weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)

Also known as: Glycerol phenylbutyrate

Verum

Placebo DRUG

Duration of Treatment: 26 weeks, twice daily Dosage: * weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo) * weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: ≥ 18 years
• "clinical possible" or "clinical probable" CBS (Armstrong et al., Neurol-ogy, 2013 80;496-503) and patients with Progressive Supranuclear Palsy-CBS according to Höglinger et al. (Mov Disord. 2017 Jun;32(6):853-864)
• No regular consumption of glycerol phenylbutyrate within the last 6 months prior to V1
• Capable of thoroughly understanding all information given and giving full informed consent according to GCP
• Capability and willingness to comply with the procedures of the clinical trial
• Women of childbearing age must be non-lactating and surgically sterile or using a highly effective method of birth control and have a nega-tive pregnancy test. In case of using a hormonal contraception, the method must be supplemented with a barrier method (preferably male condom). Acceptable methods of birth control with a low failure rate i.e. less than 1% per year when used consistently and correct are such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence (defined as refraining from heterosexual intercourse during the clinical trial) or vasectomized partner. Unacceptable birth control methods are: periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only and lactational amenorrhoea method (LAM). Female condom and male condom should not be used together.
• A stable regimen for at least 1 month prior to V1 and no foreseeable need to change the regimen throughout the 26 week treatment period for
• drugs acting against Parkinsonism (e.g. Levodopa, Dopamine-Agonists, Amantadine and MAO-B-Inhibitors)
• other CNS-active substances including e.g. antidepressants and antidementia drugs

You may not qualify if:

• Neurodegenerative diseases other than CBS
• Underlying Alzheimer's pathology as defined by positive β-amyloid-PET or reduced Aβ 1-42 in CSF
• Participation in another clinical trial involving administration of an investigational medicinal product within 1 month or 5 half-lives of the investigational medicinal product, whichever is longer, prior to V1
• Known hypersensitivity to glycerol phenylbutyrate or its further components, or to drugs with a similar chemical structure or to any of the components of the placebo
• Treatment with valproic acid, haloperidol or probenecid
• A physical or psychiatric condition (e.g. frontal lobe syndrome, psychotic disorder or major depression), which at the investigator's discretion may put the subject at risk, may confound the trial results or may interfere with the subject's participation in this clinical trial
• Persistent abuse of medication, drugs or alcohol
• Current or planned pregnancy or breast-feeding in females
• Other severe medical conditions upon the discretion of the investigator

Sponsors & Collaborators

• Technical University of Munich: lead

Study Sites (2)

Klinikum der Universität München (KUM), Campus Großhadern, Klinik und Poliklinik für Neurologie & German Center for Neurodegenerative Diseases (DZNE), Department of Neurology

Munich, Bavaria, 81377, Germany

Location

Klinikum rechts der Isar Technische Universität München Klinik und Poliklinik für Neurologie & German Center for Neurodegenerative Diseases (DZNE), Department of Neurology

Munich, Bavaria, 81377, Germany

Location

MeSH Terms

Conditions

Corticobasal Degeneration

Interventions

glycerol phenylbutyrate

Condition Hierarchy (Ancestors)

Tauopathies; Neurodegenerative Diseases; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 13, 2023
• First Posted: August 9, 2023
• Study Start: December 12, 2023
• Primary Completion: March 30, 2026
• Study Completion: March 30, 2026
• Last Updated: March 18, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)